Are clinical data from spontaneous pharmacovigilancereports transmitted via the Ministry of Health's web portal sufficient to generate a signal without further documentation?

被引：0
作者：
Grandvuillemin, Aurelie [1 ]
Jeannot, Audrey [1 ]
Valnet-Rabier, Marie-Blanche [2 ]
Pietri, Tessa [3 ]
Chouchana, Laurent [4 ]
Gautier, Sophie [5 ]
Bera, Annie-Pierre Jonville [6 ]
机构：
[1] Univ Hosp Dijon Bourgogne, Reg Pharmacovigilance Ctr Burgundy, F-21000 Dijon, France
[2] Univ Hosp Besancon, Reg Pharmacovigilance Ctr Franche Comte, F-25000 Besancon, France
[3] AP HM, Reg Pharmacovigilance Ctr Marseille, Dept Clin Pharmacol & Pharmacovigilance, F-13000 Marseille, France
[4] Cochin Hosp, AP HP, Reg Pharmacovigilance Ctr, Dept Pharmacol, Paris, France
[5] Lille Univ, Reg Parmacovigilance Ctr, Ctr Pharmacovigilance, Lille Univ Hosp,Dept Clin Pharmacol, F-59000 Lille, France
[6] Univ Hosp, Reg Pharmacovigilance Ctr Ctr Val De Loire, Dept Pharmacosurveillance, F-37000 Tours, France
来源：
THERAPIE | 2024年 / 79卷 / 04期
关键词：
Pharmacovigilance; Spontaneous report; Safety signal; Clinical data; COMPLETENESS; QUALITY; SENT;
D O I：
10.1016/j.therap.2023.10.006
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：493 / 496
页数：4
相关论文
共 10 条
  • [1] Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance
    Bate, Andrew
    Hornbuckle, Ken
    Juhaeri, Juhaeri
    Motsko, Stephen P.
    Reynolds, Robert F.
    [J]. THERAPEUTIC ADVANCES IN DRUG SAFETY, 2019, 10
  • [2] vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues
    Bergvall, Tomas
    Noren, G. Niklas
    Lindquist, Marie
    [J]. DRUG SAFETY, 2014, 37 (01) : 65 - 77
  • [3] Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study
    Durrieu, Genevieve
    Jacquot, Julien
    Mege, Mathilde
    Bondon-Guitton, Emmanuelle
    Rousseau, Vanessa
    Montastruc, Francois
    Montastruc, Jean-Louis
    [J]. DRUG SAFETY, 2016, 39 (12) : 1189 - 1195
  • [4] European Medicines Agency, 2021, M HIGHL PHARM RISK A
  • [5] Humbert X, 2019, SANTE PUBLIQUE, V31, P561, DOI 10.3917/spub.194.0561
  • [6] Ministere de la Sante et de la Prevention, 2018, Premiere evaluation du portail de signalement des evenements sanitairesindesirables
  • [7] Causality assessment in pharmacovigilance: The French method and its successive updates
    Miremont-Salame, Ghada
    Theophile, Helelne
    Haramburu, Francoise
    Begaud, Bernard
    [J]. THERAPIE, 2016, 71 (02): : 179 - 186
  • [8] Quality of Spontaneous Reports of Adverse Drug Reactions Sent to a Regional Pharmacovigilance Unit
    Salvador, Mario Rui
    Monteiro, Cristina
    Pereira, Luisa
    Duarte, Ana Paula
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (07)
  • [9] Role of spontaneous reporting in investigating the relationship between mRNA COVID-19 vaccines and myocarditis: The French perspective
    Salvo, Francesco
    Pariente, Antoine
    Valnet-Rabier, Marie Blanche
    Drici, Milou-Daniel
    Cholle, Clement
    Mathieu, Clement
    Singier, Allison
    Bagheri, Haleh
    Tebacher, Martine
    Micallef, Joelle
    Gautier, Sophie
    [J]. THERAPIE, 2023, 78 (05): : 509 - 515
  • [10] Myocarditis and pericarditis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
    Tejtel, S. Kristen Sexson
    Munoz, Flor M.
    Al-Ammouri, Iyad
    Savorgnan, Fabio
    Guggilla, Rama K.
    Khuri-Bulos, Najwa
    Phillips, Lee
    Engler, Renata J. M.
    [J]. VACCINE, 2022, 40 (10) : 1499 - 1511
1